Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry

Clinical Transplantation

Volumn 27, Issue 1, 2013, Pages 15-24

  Langone, Anthony ^a   Doria, Cataldo ^b   Greenstein, Stuart ^c   Narayanan, Mohanram ^d   Ueda, Kimi ^e   Sankari, Bashir ^f   Pankewycz, Oleh ^g   Shihab, Fuad ^h   Chan, Laurence ⁱ  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f CHARLESTON AREA MEDICAL CENTER   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

Cellcept; EC MPS; Kidney transplantation; Mycophenolate; Mycophenolate mofetil; Myfortic; Outcomes; Tacrolimus

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; TACROLIMUS;

EID: 84873099794     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01694.x     Document Type: Article

References (39)

1. Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006: 6: 1111.
2. Bunnapradist S, Ambühl PM. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clin Transplant 2008: 22: 815.
3. Knoll GA, MacDonald I, Khan A, van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003: 14: 2381.
4. Pelletier RP, Akin B, Henry ML, Elkhammas EA, Rajab A, Ferguson RM. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003: 17: 200.
5. Machnicki G, Ricci JF, Brennan DC, Schnitzler MA. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients. Pharmacoeconomics 2008: 26: 951.
6. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 2004: 17: 609.
7. Cooper M, Deering KL, Slakey DP et al. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients. Transplantation 2009: 88: 514.
8. Bunnapradist S, Lentine KL, Burroughs TE et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006: 82: 102.
9. Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson R. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal recipients. Clin Transplant 2005: 19: 779.
10. Shah S, Collett D, Johnson R, Raftery M, Rudge C, Yaqoob MM. The effect of mycophenolate mofetil and azathioprine dose on renal allograft outcome in the United Kingdom. Transplantation 2008: 86: 1035.
11. Opelz G, Döhler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008: 86: 371.
12. Khosroshahi HT, Shoja MM, Peyrovifar A, Hashemi SR, Amjadi M. Mycophenolate mofetil dose reduction in renal transplant recipients: a 5-year follow-up study. Transplant Proc 2009: 41: 2797.
13. Yeung S, Tsang WK, Tong KL et al. Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. Transplant Proc 2004: 36: 2084.
14. Salvadori M, Holzer H, de Mattos A et al., ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004: 4: 231.
15. Budde K, Curtis J, Knoll G et al., ERL B302 Study Group. Enteric-coated mycophenolate sodium can be administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004: 4: 237.
16. Langone AJ, Chan L, Bolin P, Cooper M. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. Transplantation 2011: 91: 470.
17. Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006: 81: 1290.
18. Bolin P, Tanriover B, Zibari GB et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007: 84: 1443.
19. Sollinger HW, Sundberg AK, Leverson G, Voss BJ, Pirsch JD. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients. Transplantation 2010: 89: 446.
20. Shehata M, Bhandari S, Venkat-Raman G et al. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transpl Int 2009: 22: 821.
21. Bilodeau JF, Montambault P, Wolff JL, Lemire J, Masse M. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplant Proc 2009: 41: 3683.
22. Massari P, Duro-Garcia V, Girón F et al. myPROMS LatAm Study Group. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 2005: 37: 916.
23. Sabbatini M, Capone D, Gallo R et al. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundam Clin Pharmacol 2009: 23: 617.
24. Arns W, Breuer S, Choudhury S et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005: 19: 199.
25. Ekberg H, Tedesco-Silva H, Demirbas A et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007: 357: 2562.
26. Poggio ED, Wang X, Weinstein DM et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006: 6: 100.
27. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS. RS-61443-a phase I clinical trial and pilot rescue study. Transplantation 1992: 53: 428.
28. Ekberg H, Bernasconi C, Tedesco-Silva H et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009: 9: 1876.
29. Moore J, Middleton L, Cockwell P et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systemic review and meta-analysis. Transplantation 2009: 87: 591.
30. Cosio FG, Amer H, Grande JP, Larson TS, Stegall MD, Griffin MD. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation 2007: 83: 411.
31. Sánchez-Fructuoso AI, de la Higuera MA, Giorgi M et al. Inadequate mycophenolic acid exposure and acute rejection in kidney transplantation. Transplant Proc 2009: 41: 2104.
32. Meier-Kriesche H-U, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004: 4: 378.
33. McDonald S, Russ G, Campbell S, Chadban S, On behalf of ANZDATA. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. Am J Transplant 2007: 7: 1201.
34. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant 2009: 9(Suppl 3): S1.
35. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. Br Med J 2005: 331: 810.
36. Kuypers DR, Meur YL, Cantarovich M et al. Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010: 5: 341.
37. Le Meur Y, Büchler M, Thierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007: 7: 2496.
38. Gaston RS, Kaplan B, Shah T et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the opticept trial. Am J Transplant 2009: 9: 1607.
39. van Gelder T, Silva HT, de Fijter JW et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the Fixed-Dose Concentration-Controlled Trial. Transplantation 2008: 86: 1043.